TPST Latest Headlines

Tempest Therapeutics GAAP EPS of -$0.21 beats by $0.11

at seekingalpha.com (Fri, 13-Nov 4:50 PM)

Tempest Therapeutics Exercises Rights to CD7 CAR-T Platform

at www.tipranks.com (Thu, 12-Nov 5:35 PM)

Tempest Therapeutics Stockholders Approve Key Corporate Proposals

at www.tipranks.com (Tue, 10-Nov 4:47 PM)

Tempest secures an exclusive option for a clinical-stage CD7-targeted in vivo CAR-T platform, adding a second delivery approach alongside its LNP program

Market Chameleon (Wed, 16-Sep 9:52 AM)